@article{StreckSeefriedGenestetal.2022,
  author    = {Streck, Laura Elisa and Seefried, Lothar and Genest, Franca and Reichel, Thomas and Rudert, Maximilian and Rueckl, Kilian},
  title     = {Insuffizienzfraktur der Klavikula nach Implantation einer inversen Schulterendoprothese},
  series = {Der Orthop{\"a}de},
  volume    = {51},
  journal   = {Der Orthop{\"a}de},
  number    = {3},
  doi       = {10.1007/s00132-021-04205-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-265286},
  pages     = {246-250},
  year      = {2022},
  abstract  = {Wir stellen den seltenen Fall einer Insuffizienzfraktur der Klavikula nach Implantation einer inversen Schulterendoprothese (RSA) vor. Als Ursache solcher Frakturen wird eine vermehrte Zugbelastung durch den Musculus deltoideus nach RSA diskutiert. In den wenigen verf{\"u}gbaren Fallberichten zeigten die betroffenen Patienten deutliche Funktionseinschr{\"a}nkungen. Die Versorgung erfolgte im vorliegenden Fall mit Plattenosteosynthese. Trotz intraoperativ gutem Korrekturergebnis kam es im Verlauf ohne Trauma zum Osteosyntheseversagen mit weiterer Dislokation der Fraktur.},
  language  = {de}
}
@article{SeefriedGenestBaumannetal.2022,
  author    = {Seefried, Lothar and Genest, Franca and Baumann, Jasmin and Heidemeier, Anke and Meffert, Rainer and Jakob, Franz},
  title     = {Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS)},
  series = {Journal of Bone and Mineral Research},
  volume    = {37},
  journal   = {Journal of Bone and Mineral Research},
  number    = {3},
  doi       = {10.1002/jbmr.4493},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-276368},
  pages     = {420 -- 427},
  year      = {2022},
  abstract  = {Bone marrow lesions (BML) represent areas of deteriorated bone structure and metabolism characterized by pronounced water-equivalent signaling within the trabecular bone on magnetic resonance imaging (MRI). BML are associated with repair mechanisms subsequent to various clinical conditions associated with inflammatory and non-inflammatory injury to the bone. There is no approved treatment for this condition. Bisphosphonates are known to improve bone stability in osteoporosis and other bone disorders and have been used off-label to treat BML. A randomized, triple-blind, placebo-controlled phase III trial was conducted to assess efficacy and safety of single-dose zoledronic acid (ZOL) 5 mg iv with vitamin D 1000 IU/d as opposed to placebo with vitamin D 1000 IU/d in 48 patients (randomized 2:1) with BML. Primary efficacy endpoint was reduction of edema volume 6 weeks after treatment as assessed by MRI. After treatment, mean BML volume decreased by 64.53\% (±41.92\%) in patients receiving zoledronic acid and increased by 14.43\% (±150.46\%) in the placebo group (p = 0.007). A decrease in BML volume was observed in 76.5\% of patients receiving ZOL and in 50\% of the patients receiving placebo. Pain level (visual analogue scale [VAS]) and all categories of the pain disability index (PDI) improved with ZOL versus placebo after 6 weeks but reconciled after 6 additional weeks of follow-up. Six serious adverse events occurred in 5 patients, none of which were classified as related to the study drug. No cases of osteonecrosis or fractures occurred. Therefore, single-dose zoledronic acid 5 mg iv together with vitamin D may enhance resolution of bone marrow lesions over 6 weeks along with reduction of pain compared with vitamin D supplementation only.},
  language  = {en}
}